Lymphovascular invasion predicts poor outcome of urothelial carcinoma of renal pelvis after nephroureterectomy
Article first published online: 9 DEC 2008
© 2008 THE AUTHORS. JOURNAL COMPILATION © 2008 BJU INTERNATIONAL
Volume 103, Issue 8, pages 1047–1051, April 2009
How to Cite
Chung, S.-D., Wang, S.-M., Lai, M.-K., Huang, C.-Y., Liao, C.-H., Huang, K.-H., Pu, Y.-S., Chueh, S.-C. and Yu, H.-J. (2009), Lymphovascular invasion predicts poor outcome of urothelial carcinoma of renal pelvis after nephroureterectomy. BJU International, 103: 1047–1051. doi: 10.1111/j.1464-410X.2008.08253.x
- Issue published online: 26 MAR 2009
- Article first published online: 9 DEC 2008
- Accepted for publication 21 August 2008
- urothelial carcinoma;
- lymphvascular invasion;
To evaluate the significance of lymphovascular invasion (LVI) to predict cancer-specific survival (CSS) in patients with renal pelvic urothelial carcinoma (UC).
PATIENTS AND METHODS
In all, 76 patients with primary renal pelvic UC were treated by nephroureterectomy (NU). Inclusion criteria included nonmetastatic renal pelvic UC with no previous history of bladder cancer, concomitant ureteric lesion, or neoadjuvant chemotherapy. Age, gender, adrenalectomized or not, pathological T stage, grade, and LVI were examined by univariate and multivariate analyses to determine which were independent risk factors.
In all, 38 men and 38 women were included with a mean (range) age of 66 (41–93) years. The median (range) follow-up was 48 (15–88) months. At follow-up, eight cancer-related deaths (10.5%) were censored, and 66 patients (85.9%) were alive and disease-free. LVI was the only significant predictor of CSS in the univariate and multivariate analyses.
Adrenal metastases from primary renal pelvic UCs were rare. The present results suggest that ipsilateral adrenalectomy is not necessary during radical NU for treating patients with renal pelvic UCs. LVI appears to be a better prognostic factor for predicting poor outcome of renal pelvic UC than pT stage or tumour grade when using the current tumour-nodes-metastases staging system.